BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38522696)

  • 1. Mechanisms of lipopolysaccharide protection in tumor drug-induced macrophage damage.
    Song S; Zhang X; Cui L; Wang Y; Tian X; Wang K; Ji K
    Int J Biol Macromol; 2024 May; 266(Pt 2):131006. PubMed ID: 38522696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistance related protein (ABCC1) and its role on nitrite production by the murine macrophage cell line RAW 264.7.
    Leite DF; Echevarria-Lima J; Calixto JB; Rumjanek VM
    Biochem Pharmacol; 2007 Mar; 73(5):665-74. PubMed ID: 17169333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity.
    Rocha Gda G; Oliveira RR; Kaplan MA; Gattass CR
    Eur J Pharmacol; 2014 Oct; 741():140-9. PubMed ID: 25111243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detoxification of 1-chloro-2,4-dinitrobenzene in MCF7 breast cancer cells expressing glutathione S-transferase P1-1 and/or multidrug resistance protein 1.
    Diah SK; Smitherman PK; Townsend AJ; Morrow CS
    Toxicol Appl Pharmacol; 1999 Jun; 157(2):85-93. PubMed ID: 10366541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer.
    Dong X; Sun R; Wang J; Yu S; Cui J; Guo Z; Pan X; Sun J; Yang J; Pan LL
    Biochem Pharmacol; 2020 Dec; 182():114289. PubMed ID: 33080187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
    Kim WJ; Kakehi Y; Yoshida O
    Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
    Johansson K; Ito M; Schophuizen CM; Mathew Thengumtharayil S; Heuser VD; Zhang J; Shimoji M; Vahter M; Ang WH; Dyson PJ; Shibata A; Shuto S; Ito Y; Abe H; Morgenstern R
    Mol Pharm; 2011 Oct; 8(5):1698-708. PubMed ID: 21851097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity.
    Lok HC; Sahni S; Jansson PJ; Kovacevic Z; Hawkins CL; Richardson DR
    J Biol Chem; 2016 Dec; 291(53):27042-27061. PubMed ID: 27866158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance.
    Harbottle A; Daly AK; Atherton K; Campbell FC
    Int J Cancer; 2001 Jun; 92(6):777-83. PubMed ID: 11351295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data.
    Bracht K; Liebeke M; Ritter CA; Grünert R; Bednarski PJ
    Anticancer Drugs; 2007 Apr; 18(4):389-404. PubMed ID: 17351391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.
    Zhao H; Guo W; Peng C; Ji T; Lu X
    Mol Biol Rep; 2010 Jun; 37(5):2509-15. PubMed ID: 19701692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells.
    Chen HH; Chang HH; Chang JY; Tang YC; Cheng YC; Lin LM; Cheng SY; Huang CH; Sun MW; Chen CT; Kuo CC
    Free Radic Biol Med; 2017 Dec; 113():505-518. PubMed ID: 29080842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines.
    Whelan RD; Hosking LK; Townsend AJ; Cowan KH; Hill BT
    Cancer Commun; 1989; 1(6):359-65. PubMed ID: 2702041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione S-transferase P1 suppresses iNOS protein stability in RAW264.7 macrophage-like cells after LPS stimulation.
    Cao X; Kong X; Zhou Y; Lan L; Luo L; Yin Z
    Free Radic Res; 2015; 49(12):1438-48. PubMed ID: 26361746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation and control of nitric oxide (NO) in macrophages: Protecting the "professional killer cell" from its own cytotoxic arsenal via MRP1 and GSTP1.
    Kovacevic Z; Sahni S; Lok H; Davies MJ; Wink DA; Richardson DR
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):995-999. PubMed ID: 28219722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
    Mavis CK; Morey Kinney SR; Foster BA; Karpf AR
    Prostate; 2009 Sep; 69(12):1312-24. PubMed ID: 19444856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipopolysaccharide increases the expression of multidrug resistance-associated protein 1 (MRP1) in RAW 264.7 macrophages.
    Silverstein PS; Audus KL; Qureshi N; Kumar A
    J Neuroimmune Pharmacol; 2010 Dec; 5(4):516-20. PubMed ID: 19894120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines.
    Lai GM; Moscow JA; Alvarez MG; Fojo AT; Bates SE
    Int J Cancer; 1991 Nov; 49(5):688-95. PubMed ID: 1682279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines.
    Hour TC; Chen J; Huang CY; Guan JY; Lu SH; Hsieh CY; Pu YS
    Anticancer Res; 2000; 20(5A):3221-5. PubMed ID: 11062746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
    Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.